Metabolism of the psychotomimetic tryptamine derivative 5-methoxy-N, N-diisopropyltryptamine in humans: Identification and quantification of its urinary metabolites

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 281-287

  Kamata, Tooru ^a   Katagi, Munehiro ^a   Kamata, Hiroe T ^a   Miki, Akihiro ^a   Shima, Noriaki ^a   Zaitsu, Kei ^a   Nishikawa, Mayumi ^a   Tanaka, Einosuke ^b   Honda, Katsuya ^a   Tsuchihashi, Hitoshi ^a  

^a Chuo ward   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHOXY N ISOPROPYLTRYPTAMINE; 5 METHOXY N,N DIISOPROPYLTRYPTAMINE N OXIDE; 6 HYDROXY 5 METHOXY N,N DIISOPROPYLTRYPTAMINE; DRUG METABOLITE; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE; PSYCHEDELIC AGENT; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CASE REPORT; DEMETHYLATION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SULFATION; GAS CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTION TIME; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY; URINALYSIS;

5-METHOXYTRYPTAMINE; ADULT; CHROMATOGRAPHY, LIQUID; DEMENTIA; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALLUCINOGENS; HUMANS; MALE;

EID: 31344479074     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005835     Document Type: Article

References (17)

1. Cymerman Craig J and Purushothaman KK (1970) An improved preparation of tertiary amine N-oxides. J Org Chem 35:1721-1722.
2. [DEA] Drug Enforcement Administration (DEA), Department of Justice (2001) An encounter with 5-methoxy-N,N-diisopropyltryptamine. Microgram Bull 34:126.
3. [DEA] Drug Enforcement Administration (DEA), Department of Justice (2003) Schedules of controlled substances: temporary placement of alpha- methyltryptamine and 5-methoxy-N,Ndiisopropyltryptamine into Schedule I. Final rule. Fed Regist 68:16427-164230.
4. Katagi M, Tatsuno M, Miki A, Nishikawa M, Nakajima K, and Tsuchihashi H (2001) Simultaneous determination of selegiline-N-oxide, a new indicator for selegiline administration, and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci 759:125-133.
5. Katagi M, Tatsuno M, Miki A, Nishikawa M, and Tsuchihashi H (2000) Discrimination of dimethylamphetamine and methamphetamine use: simultaneous determination of dimethylamphetamine-N-oxide and other metabolites in urine by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Anal Toxicol 24:354-358.
6. Katagi M, Tsutsumi H, Miki A, Nakajima K, and Tsuchihashi H (2002) Analysis of clandestine tablets of amphetamines and their related designer drugs encountered in recent Japan. Jpn J Forensic Toxicol 20:303-319.
7. Meatherall R and Sharma P (2003) Foxy, a designer tryptamine hallucinogen. J Anal Toxicol 27:313-317.
8. Morano RA, Spies C, Walker FB, and Plank SM (1993) Fatal intoxication involving etryptamine. J Forensic Sci 38:721-725.
9. Shulgin AT and Carter MF (1980) N,N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun Psychopharmacol 4:363-369.
10. Shulgin A and Shulgin A (1997a) TiHKAL: The Continuation, pp 527-531. Transform Press, Berkeley, CA.
11. Shulgin A and Shulgin A (1997b) TiHKAL: The Continuation, pp 473-479. Transform Press, Berkeley, CA.
12. Shulgin A and Shulgin A (1997c) TiHKAL: The Continuation, pp 503-504. Transform Press, Berkeley, CA.
13. Shulgin A and Shulgin A (1997d) TiHKAL: The Continuation, pp 508-512. Transform Press, Berkeley, CA.
14. Sitaram BR, Lockett L, Talomsin R, Blackman GL, and McLeod WR (1987) In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol 36:1509-1512.
15. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, Inoue H, Kishi T, and Tsuchihashi H (2005a) Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica 35:107-116.
16. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nishikawa M, Nakajima K, and Tsuchihashi H (2005b) Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. J Chromatogr B Biomed Sci 819:315-322.
17. Wilson JM, McGeorge F, Smolinske S, and Meatherall R (2005) A foxy intoxication. Forensic Sci Int 148:31-36.